- Home
- BEAM vs MSGE Comparison
BEAM vs MSGE Comparison
Compare BEAM & MSGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- MSGE
- Stock Information
- Founded
- BEAM 2017
- MSGE 2020
- Country
- BEAM United States
- MSGE United States
- Employees
- BEAM N/A
- MSGE N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- MSGE Services-Misc. Amusement & Recreation
- Sector
- BEAM Health Care
- MSGE Consumer Discretionary
- Exchange
- BEAM Nasdaq
- MSGE Nasdaq
- Market Cap
- BEAM 1.6B
- MSGE 1.9B
- IPO Year
- BEAM 2020
- MSGE N/A
- Fundamental
- Price
- BEAM $20.01
- MSGE $40.01
- Analyst Decision
- BEAM Strong Buy
- MSGE Strong Buy
- Analyst Count
- BEAM 11
- MSGE 6
- Target Price
- BEAM $48.90
- MSGE $49.83
- AVG Volume (30 Days)
- BEAM 2.0M
- MSGE 380.2K
- Earning Date
- BEAM 08-05-2025
- MSGE 08-15-2025
- Dividend Yield
- BEAM N/A
- MSGE N/A
- EPS Growth
- BEAM N/A
- MSGE 157.00
- EPS
- BEAM N/A
- MSGE 2.72
- Revenue
- BEAM $63,578,000.00
- MSGE $974,670,000.00
- Revenue This Year
- BEAM N/A
- MSGE N/A
- Revenue Next Year
- BEAM $8.82
- MSGE $6.68
- P/E Ratio
- BEAM N/A
- MSGE $14.68
- Revenue Growth
- BEAM N/A
- MSGE 5.81
- 52 Week Low
- BEAM $13.53
- MSGE $28.29
- 52 Week High
- BEAM $35.25
- MSGE $44.14
- Technical
- Relative Strength Index (RSI)
- BEAM 68.31
- MSGE 61.68
- Support Level
- BEAM $16.59
- MSGE $39.27
- Resistance Level
- BEAM $17.38
- MSGE $40.83
- Average True Range (ATR)
- BEAM 1.10
- MSGE 1.02
- MACD
- BEAM 0.35
- MSGE 0.02
- Stochastic Oscillator
- BEAM 89.70
- MSGE 76.02
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About MSGE Madison Square Garden Entertainment Corp.
Madison Square Garden Entertainment Corp provides live entertainment, delivering unforgettable experiences while forging deep connections with diverse and passionate audiences. The company's portfolio includes a collection of world-renowned venues - New York's Madison Square Garden, The Theater at Madison Square Garden, Radio City Music Hall, and Beacon Theatre; and The Chicago Theatre - that showcase a broad array of sporting events, concerts, family shows, and special events for millions of guests annually. In addition, the company features the original production, the Christmas Spectacular Starring the Radio City Rockettes, which has been a holiday tradition for 89 years.